Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Soulef Hachemi"'
Autor:
Carlos L. Arteaga, Mark Clemons, Soulef Hachemi, Barbara Pistilli, Javier Cortes, José Baselga, Zefei Jiang, Norikazu Masuda, Agnieszka Jagiełło-Gruszfeld, Bharani Dharan, Seock–Ah –A Im, Masato Takahashi, Patrick Urban, Peter Vuylsteke, Ling Ming Tseng, Hiroji Iwata, Mario Campone, Walter Jonat, Yoshinori Ito, Sara A. Hurvitz, Ahmad Awada, Michele De Laurentiis, Cristian Massacesi, Stephen Chia, Emmanuelle di Tomaso
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
The Lancet. Oncology, vol 18, iss 7
Consejería de Sanidad de la Comunidad de Madrid
The Lancet. Oncology, vol 18, iss 7
BackgroundPhosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study assessed the efficacy of the pan-PI3K inhibitor buparlisib plus fulvestrant in
Publikováno v:
International Immunology. 12:385-395
Using an 'oligoclonal' model, we have previously shown that mice transgenic for a mu chain (H3) and deficient for kappa chain expression display a mature B cell repertoire largely dominated by the H3/lambda1 pair, while the four H3/lambda available c
Autor:
Evelyne Jouvin-Marche, Serge M. Candéias, Catherine Aude-Garcia, Soulef Hachemi-Rachedi, Patrice N. Marche, Hanne Gahéry-Ségard, Eve Borel, Pierre-André Cazenave
Publikováno v:
European Journal of Immunology. 28:818-827
The genes coding for TCR alpha and delta chains share the same genetic locus (TCRA/D). The rules governing the utilization of a V gene with the alpha and delta chains have not been established. More specifically, it is not known whether the position
Autor:
Soulef Hachemi-Rachedi, Pierre-André Cazenave, Ana Cumano, Anne-Marie Drapier, Pierre Sanchez
Publikováno v:
European Journal of Immunology. 27:1069-1074
To know whether each newly formed B cell has an equal chance of survival in the organism, we analyzed the composition of the B cell repertoire of extremely limited diversity by generating mu-transgenic kappa-knockout mice. Surprisingly, in both types
Autor:
Zora Neskovic-Konstantinovic, Mizue Krygowski, Stephen Brincat, Pierre Fumoleau, Igor Bondarenko, Arlene Chan, Maria Cincotta, Soulef Hachemi, Ann A. Lazar, Rodrigo C. Guimaraes, Daniel F. Hayes, Yan Sun, Louis W.C. Chow, Laurence Moore, Andrew Strahs, August Garin, Anna Berkenblit, Antonio C. Wolff, Lih Lisa Kang
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 31, iss 2
Purpose Recent data showed improvement in progression-free survival (PFS) when adding everolimus to exemestane in patients with advanced breast cancer experiencing recurrence/progression after nonsteroidal aromatase inhibitor (AI) therapy. Here, we r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdc3358710aad14e342b12a6c5c738a9
https://escholarship.org/uc/item/3pn24060
https://escholarship.org/uc/item/3pn24060
Autor:
S-A Im, M. Campone, J. Baselga, Yoshinori Ito, M. De Laurentiis, Agnieszka Jagiełło-Gruszfeld, J. Cortes, Walter Jonat, Patrick Urban, Cristian Massacesi, S Hurvitz, Noriyuki Masuda, E. di Tomaso, H. Iwata, Soulef Hachemi, CL Arteaga, Ahmad Awada, L-M Tseng, Zefei Jiang, S Le Mouhaër, S Chia, Mark Clemons, Barbara Pistilli
Publikováno v:
Cancer Research. 76:S6-01
Background: PI3K pathway activation is a hallmark of hormone receptor-positive (HR+) BC cells resistant to endocrine therapy (ET). Preclinical and early clinical data suggest that combining the pan-PI3K inhibitor BUP (BKM120) with ET may provide clin
Autor:
E. di Tomaso, J. Cortes, Cristian Massacesi, H. Iwata, M. Campone, S. Goteti, J. Baselga, C. Germa, Soulef Hachemi, M. De Laurentiis, CL Arteaga, Walter Jonat
Publikováno v:
Cancer Research. 72:OT2-3
Background: The PI3K/AKT/mTOR pathway has been reported altered in up to 40% of hormone receptor-positive (HR+) breast cancers (BC). Furthermore, pathway activation has been implicated in resistance to endocrine therapy, including aromatase inhibitor
Publikováno v:
The Antibodies
The antibodies
The antibodies, Harwood Academic Publishers, 1998
The antibodies
The antibodies, Harwood Academic Publishers, 1998
173 refs. *INRA, Unité de Virologie et Immunologie Moléculaires, Jouy en Josas; International audience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab37c47fef8532693963bea48f253632
https://doi.org/10.1201/9781482283617-4
https://doi.org/10.1201/9781482283617-4